These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation. Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373 [TBL] [Abstract][Full Text] [Related]
7. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661 [TBL] [Abstract][Full Text] [Related]
8. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition. Huang J; Rebello SS; Faul JD; Lucchesi BR Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466 [TBL] [Abstract][Full Text] [Related]
9. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery. Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011 [TBL] [Abstract][Full Text] [Related]
10. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist. Lucchessi BR; Rote WE; Driscoll EM; Mu DX Br J Pharmacol; 1994 Dec; 113(4):1333-43. PubMed ID: 7889289 [TBL] [Abstract][Full Text] [Related]
11. Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs. Mousa SA; Mu DX; Lucchesi BR Stroke; 1997 Apr; 28(4):830-5; discussion 835-6. PubMed ID: 9099204 [TBL] [Abstract][Full Text] [Related]
12. Prevention of carotid artery thrombosis after oral administration of the glycoprotein IIb/IIIa antagonist CRL42796. Hennan JK; Willens DE; Driscoll EM; Hong TT; Giboulot T; Lucchesi BR J Cardiovasc Pharmacol; 2003 Jul; 42(1):71-7. PubMed ID: 12827029 [TBL] [Abstract][Full Text] [Related]
13. In vivo efficacy of SM-20302, a GP IIb/IIIa receptor antagonist, correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood. Rebello SS; Huang J; Saito K; Lucchesi BR Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):954-60. PubMed ID: 9633937 [TBL] [Abstract][Full Text] [Related]
14. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728. Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524 [TBL] [Abstract][Full Text] [Related]
15. Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis. Werns SW; Rote WE; Davis JH; Guevara T; Lucchesi BR Am Heart J; 1994 Apr; 127(4 Pt 1):727-37. PubMed ID: 8154409 [TBL] [Abstract][Full Text] [Related]